AstraZeneca
AstraZeneca vs GSK: Cancer drug court battle could cost hundreds of millions
June 7, 2021Sales and Marketing AstraZeneca, GSK, court
AstraZeneca has launched a court case against Glaxo Smith Kline (GSK), in a claim that could reach hundreds of millions …
AstraZeneca’s lung cancer drug gains EU approval
May 28, 2021Medical Communications AstraZeneca, EU, lung cancer, oncology
AstraZeneca’s Tagrisso (osimertinib) has been approved in the EU for the adjuvant treatment of adult patients with early-stage (IB, II …
AstraZeneca and Amgen asthma drug shows positive results in Phase III trial
May 13, 2021Amgen, AstraZeneca, asthma, asthma treatment, pharma, pharma news, severe asthma
AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority across all primary and secondary …
AstraZeneca to collaborate with Alchemab on prostate cancer research
May 6, 2021AstraZeneca, prostate cancer
AstraZeneca have announced a new collaboration with Cambridge-based biotech company Alchemab, with the aim of accelerating prostate cancer research. Alchemab …
AstraZeneca drug approved by FDA for kidney disease treatment
May 4, 2021Manufacturing and Production AstraZeneca, FDA, kidney disease, pharma, pharma news
AstraZeneca’s Farxiga drug has been approved for the treatment of chronic kidney disease (CKD) in the US by the FDA.
European Commission sues AstraZeneca over COVID-19 jab supplies
April 27, 2021Manufacturing and Production AstraZeneca, AstraZeneca vaccine, COVID-19, EU, European Commission, covid 19 news, covid-19 news, european union, pharma, pharma news
The European Commission (EC) announced yesterday that it was suing AstraZeneca for failing to respect its contract to supply COVID-19 …
Sanofi’s RSV drug sees Phase III clinical trial success
April 26, 2021Sales and Marketing AstraZeneca, Sanofi
Sanofi have announced positive topline results from the Phase III MELODY trial into nirsevimab, which demonstrated protection against respiratory syncytial …
AstraZeneca drug evaluated in nine eosinophilic diseases
April 23, 2021Medical Communications AstraZeneca
AstraZeneca announced on Thursday that the first patients had been dosed in the Phase III Fasenra (benralizumab) clinical trial in …
Enhertu now available via Cancer Drugs Fund following NICE decision
April 20, 2021Manufacturing and Production AstraZeneca, breast cancer, oncology
AstraZeneca and Daiichi Sankyo have announced that NICE has approved Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund …
Forxiga accepted for use within NHS Scotland for chronic heart failure
April 14, 2021Research and Development AstraZeneca, nhs scotland
AstraZeneca have announced that Forxiga (dapagliflozin) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) …
AstraZeneca’s Farxiga falls short in Phase III trials for treatment of COVID-19
April 13, 2021Manufacturing and Production AstraZeneca, COVID-19, covid-19 treatment, farxiga, pharma, pharma news
AstraZeneca’s Farxiga drug, usually used in patients with diabetes, did not show statistical significance in the Phase III trial into …
AstraZeneca halt paediatric trial of COVID-19 vaccine amid blood clot probe
April 7, 2021Research and Development AstraZeneca, COVID-19, Vaccine
AstraZeneca has halted the trial of its COVID-19 vaccine on children aged between 6 and 17, while regulators investigate a …
AstraZeneca vaccine found to be 3% less effective after further trial analysis
March 25, 2021AstraZeneca, AstraZeneca vaccine, COVID-19, COVID-19 vaccine, Vaccine
AstraZeneca have revised their findings from the US study AZD1222 of their COVID-19 vaccine, announcing a 76% efficacy against symptoms …
AstraZeneca COVID-19 vaccine deemed “safe and effective” by EMA
March 19, 2021Medical Communications AstraZeneca, COVID-19, EMA, Vaccine
AstraZeneca’s COVID-19 vaccine has been cleared for continued use by the EMA following an investigation into the reports of 37 …
AstraZeneca & MSD ovarian cancer drug combination approved by NICE
March 19, 2021Medical Communications AstraZeneca, MSD, NICE, oncology
A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
